spacer
home > ict > winter 2021 > the future of rare disease therapies
PUBLICATIONS
International Clinical Trials

The Future of Rare Disease Therapies


ICT: How do you see the landscape of gene therapy trials for rare diseases looking in the future?

Dr Matthew Klein: Ever since the human genome was cloned, there has been the potential for using gene therapy to target diseases, particularly rare diseases, many of which result from missing or inactive genes. Over the past few years, we have finally caught up in terms of having the necessary understanding, technology, and experience to not only discover potential gene therapies, but develop them. What we’re seeing right now, not surprisingly, is an explosive growth in the development of gene therapies targeting rare diseases because there’s always been a lot of understanding that rare diseases typically result from biological defects related to missing or inactive genes. The landscape now is chock full of efforts looking at gene therapies for rare diseases, and I think that’s going to be increasingly the case. It's really an exciting time for gene therapy, and gene therapy for rare diseases.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Matthew B Klein, MD, MS, FACS is Chief Development Officer at PTC Therapeutics. Prior to joining PTC, Matthew was CEO and Chief Medical Officer of BioElectron Technology Corporation, a biotechnology company focused on developing redox active small molecules for mitochondrial disease and related disorders of oxidative stress. Prior to joining BioElectron, he was the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. Dr Klein completed his undergraduate degree at the University of Pennsylvania, US, where he graduated summa cum laude and Phi Beta Kappa, and received his MD degree with honours from Yale University, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer

Cambridge, UK, 14 June 2022: Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of superior and differentiated ADCs in the treatment of solid tumours where there is a high unmet need.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement